Literature DB >> 3363166

Effect of brofaromine and pargyline on human plasma melatonin concentrations.

P R Bieck1, K H Antonin, R Balon, G Oxenkrug.   

Abstract

1. Plasma melatonin was used to determine the influence of two monoamine oxidase inhibitor drugs in 11 normal subjects. 2. Acute oral administration of the selective reversible MAO-A inhibitor brofaromine but not of the - in low doses - selective MAO-B inhibitor pargyline increased daytime melatonin with large variations in onset, degree and duration. 3. Further investigation of this selective action on melatonin might help to better understand the action of the therapeutically effective antidepressive therapy with selective MAO-A inhibitors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3363166     DOI: 10.1016/0278-5846(88)90064-4

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  4 in total

Review 1.  90 years of monoamine oxidase: some progress and some confusion.

Authors:  Keith F Tipton
Journal:  J Neural Transm (Vienna)       Date:  2018-04-10       Impact factor: 3.575

2.  Chemical sympathectomy and clorgyline-induced stimulation of rat pineal melatonin synthesis.

Authors:  S Reuss; G F Oxenkrug
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

3.  Effects of chronic brofaromine administration on biogenic amines including sulphatoxymelatonin and acid metabolites in patients with bulimia nervosa.

Authors:  S H Kennedy; B A Davis; G M Brown; C G Ford; J d'Souza
Journal:  Neurochem Res       Date:  1993-12       Impact factor: 3.996

Review 4.  Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.

Authors:  N P Nair; S K Ahmed; N M Kin
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.